Safety and efficacy of leadless pacemaker for cardioinhibitory vasovagal syncope

Turagam, Mohit K.; Gopinathannair, Rakesh; Park, Peter H.; Tummala, Rangarao; Vasamreddy, Chandrasekhar R.; Shah, Alap; Koerber, Scott; Krauthammer, Yoaav; Biase, Luigi Di; Murtaza, Ghulam; Akella, Krishna; Atkins, Donita; Bommana, Sudharani; Kodwani, Naresh; Romero, Jorge; Al‐Ahmad, Amin; Lakkireddy, Prajwala; Rocca, Domenico G. Della; Mohanty, Sanghamitra; Gwon, Yeongjin; Lakkireddy, Dhanunjaya

doi:10.1016/j.hrthm.2020.05.006

Cited by 22 publications

(15 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There were 5 major adverse events in the transvenous pacing group and 2 in the LP group (10.4% vs 8.3%; P = 1.00). The authors of the study concluded that the safety and efficacy of single‐chamber LPs are comparable with conventional dual‐chamber transvenous pacemakers in patients with cardioinhibitory vasovagal syncope on intermediate‐term follow‐up 18 …”

Section: Discussionmentioning

confidence: 99%

“…Studies on the use of LPs for cardioinhibitory vasovagal population specifically, concluded that the safety and efficacy of LPs are comparable with TV-PPM. 8,9 In addition, it is also demonstrated that LPs are associated with better quality of life than TV-PPM. 10 At the end of battery life, a reasonable strategy might be to implant another LP without extracting the old one.…”

Section: F I G U R E 1 2021 Esc Guidelines On Cardiac Pacing and Card...mentioning

confidence: 99%

“…The authors of the study concluded that the safety and efficacy of single-chamber LPs are comparable with conventional dual-chamber transvenous pacemakers in patients with cardioinhibitory vasovagal syncope on intermediate-term follow-up. 18 Based on these studies, implanting a leadless pacemaker might be considered a reasonable option in patients with profound bradycardia associated with cardioinhibitory vasovagal syncope.…”

Section: Leadless Pacing Experience In Vasovagal Syncope Patientsmentioning

confidence: 99%

See 2 more Smart Citations

A leadless pacemaker matched with a vasovagal syncope: how long can it last?

ElRefai

Menexi

Abouelasaad

et al. 2022

Pacing Clinical Electrophis

View full text Add to dashboard Cite

Background Guidelines recommend that cardiac pacing should be considered in patients suffering from frequent vasovagal syncopal (VVS) episodes. Studies have demonstrated the safety and efficacy of leadless pacemakers (LP) in cardioinhibitory vasovagal populations specifically, rendering them a reasonable alternative to transvenous pacing in these patients. However, due to the paucity of data on extraction and the number of concomitant LPs that can be safely implanted, there are concerns regarding LPs’ battery longevity, especially in younger patients who may require decades of pacing therapy. Methods This is a retrospective analysis of the first 100 LPs implanted at a tertiary cardiac centre in the UK. Demographical data and device parameters at implant and follow‐ups were obtained from the hospital's medical records. The battery life of the LPs in the VVS patients was compared to that of patients with other pacing indications. Results Ninety patients were included in the analysis. 14 patients (15.6%) had VVS, and 76 patients (84.4%) had other indications for pacing. Mean ages were 34 ± 13 years and 62 ± 20 years for the VVS and the other group, respectively. The estimated total battery life was 15.22 ± 0.35 and 13.65 ± 2.97 years in the VVS and the other indications group respectively (p = .04). There were no complications in the VVS group. Conclusion LPs provide a promising treatment for patients with vasovagal syncope with reassuring battery performance at the short/intermediate term. Further longer‐term follow‐up data are needed to identify the true battery potential in this patient cohort.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: F I G U R E 1 2021 Esc Guidelines On Cardiac Pacing and Card...mentioning

confidence: 99%

Section: Leadless Pacing Experience In Vasovagal Syncope Patientsmentioning

confidence: 99%

See 1 more Smart Citation

A leadless pacemaker matched with a vasovagal syncope: how long can it last?

ElRefai

Menexi

Abouelasaad

et al. 2022

Pacing Clinical Electrophis

View full text Add to dashboard Cite

show abstract

“…Conventional treatments, such as tilt-training and medicine, have been shown to have limited efficacy [2][3][4] ; pacemaker therapy may be beneficial in some patients. 5,6 Autonomic modification through catheter ablation of ganglionated plexi (GP) in the left atrium has been reported effective in several previous studies. 7,8 Our case documents the manifestation and investigation of a young man who experienced several episodes of syncope after exercise and was treated successfully with left atrial GP ablation.…”

Section: Introductionmentioning

confidence: 99%

Ganglionated plexi ablation to treat exercise-induced vasovagal syncope: A case report

Hong¹,

Jiang²,

Zhu³

et al. 2020

HeartRhythm Case Reports

View full text Add to dashboard Cite

“…Single‐chamber LLPMs have been shown to be a safe and effective alternative to TVPM, also in the context of cardioinhibitory vasovagal syncope (CI‐VVS). Following a smaller observational retrospective study with encouraging results, 35 Turagam et al 36 recently conducted a multicenter, retrospective study on 72 patients comparing those who received LP or dual‐chamber TVPM for drug‐refractory CI‐VVS. The primary efficacy endpoint was freedom from syncope during follow‐up.…”

Section: Introductionmentioning

confidence: 99%

Leadless pacemaker: State of the art and incoming developments to broaden indications

Curnis

Salghetti

Cerini

et al. 2020

Pacing Clinical Electrophis

View full text Add to dashboard Cite

Theleadless pacemaker (LLPM) therapy has been developed in recent years to overcome the transvenous lead and device pocket‐related complications. The LLPMs now available are self‐contained right ventricular pacemakers and are limited to single‐chamber ventricular pacing modality. This literature review deals with the current status of LLPM technology and current areas of clinical applicability. The safety and efficacy outcomes published from randomized clinical trials and real world registries are analyzed and compared with historical conventional transvenous pacemaker data. Furthermore, new pacing modalities and future perspectives to broaden the clinical use and cover most of pacing indications are discussed. Due to the overall safe and effective profile in the short term and intermediate term, also in fragile patients, the LLPM use is constantly growing in daily clinical practice. Actually, it can be considered a landmark innovation, through which a new era of cardiac pacing has begun.

show abstract

Safety and efficacy of leadless pacemaker for cardioinhibitory vasovagal syncope

Cited by 22 publications

References 23 publications

A leadless pacemaker matched with a vasovagal syncope: how long can it last?

A leadless pacemaker matched with a vasovagal syncope: how long can it last?

Ganglionated plexi ablation to treat exercise-induced vasovagal syncope: A case report

Leadless pacemaker: State of the art and incoming developments to broaden indications

Contact Info

Product

Resources

About